LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

Home・Stock List・Kura Oncology Inc

Kura Oncology Inc

Closed

SectorHealthcare

9.74 2.96

Buy Sell

Overview

Share price change

24h

Current

Min

9.43

Max

9.98

Key metrics
By Trading Economics
Income	-6.9M -81M
Sales	-3.4M 17M
Profit margin	-467.23
Employees	260
EBITDA	-12M -86M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+196.73% upside

Dividends
By Dow Jones
Next Earnings	6 Aug 2026

Market Stats
By TradingEconomics
Market Cap	89M 844M
Previous open	6.78
Previous close	9.74

News Sentiment

By Acuity

50%

171 / 346 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

5.575 / 6.6 Support & Resistance

Kura Oncology Inc Chart

Past performance is not a reliable indicator of future results.

Related News

14 May 2026, 22:44 UTC

Acquisitions, Mergers, Takeovers

LVMH to Sell Marc Jacobs Fashion Brand to WHP, G-III Apparel -- 2nd Update

14 May 2026, 22:27 UTC

Acquisitions, Mergers, Takeovers

LVMH Selling Marc Jacobs Fashion Brand to WHP, G-III Apparel -- Update

14 May 2026, 22:12 UTC

Earnings

Applied Materials Raises Outlook as Semiconductor Equipment Demand Grows -- 2nd Update

14 May 2026, 21:52 UTC

Acquisitions, Mergers, Takeovers

LVMH to Sell Marc Jacobs

15 May 2026, 00:00 UTC

Earnings

Honda's Never Faced a Crisis Like This -- And a Comeback Won't Be Easy -- WSJ

14 May 2026, 23:57 UTC

Acquisitions, Mergers, Takeovers

Kakao: Stake Sales Aim to Secure Funds for Future Investments

14 May 2026, 23:56 UTC

Acquisitions, Mergers, Takeovers

Kakao: Share Sale to Lower Kakao Investment's Stake in Dunmau to 4.03%

14 May 2026, 23:56 UTC

Acquisitions, Mergers, Takeovers

Kakao: Affiliate Kakao Investment to Sell 2.3M Dunamu Shares on June 15

14 May 2026, 23:56 UTC

Market Talk

Gold Prices Rise on Strong Demand -- Market Talk

14 May 2026, 23:56 UTC

Acquisitions, Mergers, Takeovers

Kakao to Sell 6.55% Stake in Crypto Exchange Operator Dunamu to Hana Financial for KRW1.003T

14 May 2026, 23:50 UTC

Market Talk

Global Equities Roundup: Market Talk

14 May 2026, 23:50 UTC

Market Talk

Nikkei May Rise as AI Enthusiasm Continues -- Market Talk

14 May 2026, 23:47 UTC

Earnings

JSW Steel: Prolonged Supply-Chain Disruptions Due to Middle East Crisis Pose Risk to Growth >500228.BY

14 May 2026, 23:47 UTC

Earnings

JSW Steel Results Supported by Higher Steel Prices, One-Off Divestment Gains >500228.BY

14 May 2026, 23:46 UTC

Earnings

JSW Steel 4Q Net INR163.7B Vs. Net INR21.39B >500228.BY

14 May 2026, 23:46 UTC

Earnings

JSW Steel 4Q Rev INR511.8B Vs. INR448.19B >500228.BY

14 May 2026, 23:28 UTC

Market Talk

New Zealand's Economy Faltering Amid Shocks -- Market Talk

14 May 2026, 23:00 UTC

Market Talk

Australia's One Nation Party Leads In The Polls -- Market Talk

14 May 2026, 22:46 UTC

Market Talk

Global Equities Roundup: Market Talk

14 May 2026, 22:46 UTC

Market Talk

Court Decision 'Negative But Balanced' for Coles -- Market Talk

14 May 2026, 22:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14 May 2026, 22:35 UTC

Market Talk

Fed's Warsh Talks Big Game; Will Focus On Credibility First -- Market Talk

14 May 2026, 22:11 UTC

Acquisitions, Mergers, Takeovers

LVMH Agrees to Sell Marc Jacobs -- WSJ

14 May 2026, 22:06 UTC

Market Talk

Applied Materials Gets Improved Visibility into Customer Orders -- Market Talk

14 May 2026, 22:04 UTC

Earnings

Thai Beverage Results Supported by Higher Contributions From Spritis Business >Y92.SG

14 May 2026, 22:04 UTC

Earnings

Thai Beverage 2Q Net THB7.37B Vs. Net THB6.74B >Y92.SG

14 May 2026, 22:04 UTC

Earnings

Thai Beverage 2Q Rev THB86.52B Vs. THB85.35B >Y92.SG

14 May 2026, 22:00 UTC

Earnings

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

14 May 2026, 21:55 UTC

Earnings

Nu Holdings 1Q EPS 18c >NU

14 May 2026, 21:55 UTC

Earnings

Nu Holdings 1Q Rev $4.97B >NU

Peer Comparison

Price change

Kura Oncology Inc Forecast

Price Target

By TipRanks

196.73% upside

12 Months Forecast

Average 28.13 USD 196.73%

High 40 USD

Low 15 USD

Based on 10 Wall Street analysts offering 12 month price targets forKura Oncology Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

10 ratings

Buy

Hold

Sell

Based on 10 analysts giving stock ratings to Kura Oncology Inc - Dist in the past 3 months.

Technical Score

By Trading Central

5.575 / 6.6Support & Resistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

171 / 346 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.